Skip to main
BMY

Bristol-Myers (BMY) Stock Forecast & Price Target

Bristol-Myers (BMY) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 29%
Buy 21%
Hold 43%
Sell 7%
Strong Sell 0%

Bulls say

Bristol-Myers Squibb is experiencing a positive shift in its outlook due to increased probability of success (PoS) for key drug candidates, with milvexian and iber/mezi now projected to contribute a combined risk-adjusted sales of approximately $4.8 billion by 2033. The company's robust guidance surpasses sell-side consensus, alleviating previous market concerns and fostering optimism regarding its pipeline, particularly in the immuno-oncology and cardiovascular sectors. Furthermore, the firm maintains a strong financial position characterized by effective cost management, stable growth from its existing portfolio, and the provision of a sustainable dividend, all contributing to a solid foundation for future growth.

Bears say

Bristol-Myers Squibb's stock faces a negative outlook due to significant delays in the regulatory approval and launch of new products, which could adversely affect revenues and earnings. The company's valuation remains below the average forward EV/EBITDA multiple of its peer group, indicating potential underperformance compared to competitors. Additionally, risks associated with clinical trials, such as regulatory setbacks and evolving market preferences, further exacerbate concerns about the firm's ability to maintain its competitive edge in the pharmaceutical market.

Bristol-Myers (BMY) has been analyzed by 14 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 21% recommend Buy, 43% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bristol-Myers and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bristol-Myers (BMY) Forecast

Analysts have given Bristol-Myers (BMY) a Buy based on their latest research and market trends.

According to 14 analysts, Bristol-Myers (BMY) has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $62.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $62.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bristol-Myers (BMY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.